CLINICAL_TRIALS
trial_result
· 2016-04-06
Clinical Trial Update: Pioglitazone for Oral Premalignant Lesions [Phase 2]
Summary
Phase 2 trial evaluating pioglitazone for oral premalignant lesions (oral leukoplakia) was terminated, with results posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Oral Leukoplakia | Phase 2 | Status: TERMINATED | Results posted: 2016-04-06